Genoway (ALGEN) - Total Liabilities
Based on the latest financial reports, Genoway (ALGEN) has total liabilities worth €20.43 Million EUR (≈ $23.89 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Genoway net asset momentum to track the company's year-over-year net asset growth rate.
Genoway - Total Liabilities Trend (2004–2024)
This chart illustrates how Genoway's total liabilities have evolved over time, based on quarterly financial data. See Genoway free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Genoway Competitors by Total Liabilities
The table below lists competitors of Genoway ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Digital Brands Group, Inc. Common Stock
NASDAQ:DBGI
|
USA | $25.21 Million |
|
Hep Tech Co Ltd
TWO:3609
|
Taiwan | NT$627.55 Million |
|
Unifin Financiera S. A. B. de C. V
MX:UNIFINA
|
Mexico | MX$83.80 Billion |
|
Battalion Oil Corp
NYSE MKT:BATL
|
USA | $511.94 Million |
|
Gabriel Resources Ltd
V:GBU
|
Canada | CA$23.73 Million |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
India | Rs3.76 Billion |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
Germany | €11.50 Million |
|
Midland Exploration Inc
V:MD
|
Canada | CA$2.11 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Genoway's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Genoway.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genoway's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genoway (2004–2024)
The table below shows the annual total liabilities of Genoway from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €13.23 Million ≈ $15.46 Million |
-8.54% |
| 2023-12-31 | €14.46 Million ≈ $16.90 Million |
-13.71% |
| 2022-12-31 | €16.76 Million ≈ $19.59 Million |
-6.59% |
| 2021-12-31 | €17.94 Million ≈ $20.97 Million |
-3.40% |
| 2020-12-31 | €18.57 Million ≈ $21.71 Million |
+50.86% |
| 2019-12-31 | €12.31 Million ≈ $14.39 Million |
+4.35% |
| 2018-12-31 | €11.80 Million ≈ $13.79 Million |
+18.25% |
| 2017-12-31 | €9.98 Million ≈ $11.66 Million |
+54.90% |
| 2016-12-31 | €6.44 Million ≈ $7.53 Million |
+5.62% |
| 2015-12-31 | €6.10 Million ≈ $7.13 Million |
+16.59% |
| 2014-12-31 | €5.23 Million ≈ $6.12 Million |
+12.63% |
| 2013-12-31 | €4.64 Million ≈ $5.43 Million |
-18.53% |
| 2012-12-31 | €5.70 Million ≈ $6.66 Million |
-1.31% |
| 2011-12-31 | €5.78 Million ≈ $6.75 Million |
-15.47% |
| 2010-12-31 | €6.83 Million ≈ $7.99 Million |
-6.98% |
| 2009-12-31 | €7.35 Million ≈ $8.59 Million |
+7.59% |
| 2008-12-31 | €6.83 Million ≈ $7.98 Million |
+19.20% |
| 2007-12-31 | €5.73 Million ≈ $6.70 Million |
-17.87% |
| 2006-12-31 | €6.97 Million ≈ $8.15 Million |
+16.76% |
| 2005-12-31 | €5.97 Million ≈ $6.98 Million |
+69.98% |
| 2004-12-31 | €3.51 Million ≈ $4.11 Million |
-- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more